Results 61 to 70 of about 21,646 (232)
Dabigatran pharmacokinetics (PK).
, 2019 PK of dabigatran etexilate administrated by one dose of 10 mg/kg intraperitoneal. Plasma dabigatran (p-dabigatran) were measured in two healthy rats at each time point (n = 14).
Jens Peter Goetze (316975) +9 more
core +1 more source
Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice. [PDF]
, 2016 Background. Immediate reversal of anticoagulation is essential when facing severe bleeding or emergency surgery. Although idarucizumab is approved for the reversal of dabigatran in many countries, clinical experiences are lacking, particularly in special
Sauter, Thomas +5 more
core +1 more source
International Journal of Dental Hygiene, EarlyView.ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton +5 more
wiley +1 more source
Dabigatran Associated Leukocytoclastic Vasculitis [PDF]
, 2015 Common side effects of dabigatran are bleeding, bruising, nausea, diarrhea, and abdomen discomfort. Skin reactions were not often noted (
Evangelos Potolidis +5 more
core +1 more source
Dabigatran etexilate and COVID-19
, 2021 Thrombotic complications are frequent in COVID-19. There is evidence supporting the use of prophylactic dose low molecular weight heparin (LMWH) as prophylaxis for venous thromboembolism in critically ill patients. Indeed, all patients with COVID-19 that
Domina Petric
core +1 more source
DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS
Атеротромбоз, 2015 This article discusses the significant features and use of new oral anticoagulant dabigatran etexilate for the treatment of venous thromboembolic complications (VTC).
N. M. Vorobieva, E. P. Panchenko
doaj +1 more source
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction Lupus anticoagulant (LA) testing is essential, albeit complex, in the laboratory diagnosis of antiphospholipid syndrome (APS). Given the multi‐step workflow and the variability introduced by anticoagulant therapy, reagent differences, and interpretive approaches, result interpretation requires expert evaluation.
Chiara Novelli +4 more
wiley +1 more source
Geographical variability in dabigatran dosing within New Zealand
Internal Medicine Journal, EarlyView.Abstract Dabigatran etexilate is an oral anticoagulant with increased risk of bleeding at high drug exposure. It is available in three capsule strengths (75, 110 and 150 mg). We analysed New Zealand dispensing data from 2019 to 2023 to compare use between health districts. Overall use was similar across districts.
Liam T. Berryman +4 more
wiley +1 more source
Journal of Cardiovascular Electrophysiology, EarlyView.Zero‐contrast left atrial appendage occlusion yielded high procedural success and similar periprocedural adverse event rates compared to the contrast‐guided approach. At 45‐day follow‐up, successful LAA closure (defined as peri‐device leak ≤ 5 mm) and device‐related thrombus rates were similar.
Joe Demian +12 more
wiley +1 more source
Drug-Induced Exanthem Following Dabigatran
, 2011 Objective: To report an incident of a drug-induced exanthem during treatment with dabigatran in a patient without prior exposure to the drug. Case Summary: A 20-year-old white male was prescribed oral dabigatran 150 mg twice daily for thromboembolic ...
John Hummel +3 more
core +1 more source